AbbVie and Amgen lock horns in the latest squabble over biosimilars

(By Ed Silverman for STAT)

In the latest contest over biosimilars, AbbVie has filed a patent infringement lawsuit against Amgen, an erstwhile rival in the market for hard-to-make treatments for rheumatoid arthritis. And the move highlights a strategy designed to indefinitely delay the arrival of a lower-cost biosimilar indefinitely while the litigation plays out. Continue reading article here…..


Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or